论文部分内容阅读
目的观察长春瑞滨联合卡铂治疗晚期非小细胞肺癌患者的临床疗效。方法选择2010年1月-2014年12月在医院接受治疗的晚期非小细胞肺癌患者130例,将其随机分为观察组和对照组各65例,对照组采用单纯放疗治疗,观察组应用长春瑞滨联合卡铂同步放疗治疗,对比2组患者的治疗效果。结果观察组总有效率为72.3%远高于对照组的43.1%,观察组1年后和平均生存时间均显著高于对照组,差异均有统计学意义(P<0.05)。结论长春瑞滨联合卡铂同步放疗治疗应用于晚期非小细胞肺癌的治疗取得了良好的临床疗效,大大提高了治疗的总有效率,延长了患者的生存时间,值得大力推广。
Objective To observe the clinical efficacy of vinorelbine plus carboplatin in the treatment of advanced non-small cell lung cancer. Methods 130 patients with advanced non-small cell lung cancer who were treated in the hospital from January 2010 to December 2014 were randomly divided into observation group (65 cases) and control group (65 cases). The control group received radiotherapy alone and the observation group Rebar combined carboplatin simultaneous radiotherapy treatment, the treatment of patients in two groups compared. Results The total effective rate in the observation group was 72.3%, which was significantly higher than that in the control group (43.1%). The average survival time in the observation group after 1 year was significantly higher than that in the control group (P <0.05). Conclusion The combination of vinorelbine and carboplatin in the treatment of advanced non-small cell lung cancer has achieved good clinical efficacy, greatly improving the total effective rate of treatment and prolonging the survival time of patients, which is worth to be promoted.